drug
nirsevimab
Marketedupdated 6mo agoby Sanofi-Aventis US LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
all catalysts(5)
approval · 5
Jul 17, 2023
approval
$AZN178.76-1.93%
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Feb 23, 2024
approval
$AZN178.76-1.93%
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Aug 22, 2024
approval
$AZN178.76-1.93%
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Oct 20, 2025
approval
$AZN178.76-1.93%
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Apr 7, 2026
approval
$AZN178.76-1.93%
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Trials studying nirsevimab
- —A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
- —An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia
- —RSV Immunisation Status in Queensland (Australia)
- phase3A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
- phase3Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China
- phase4Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
- phase2Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants
- EP1A Clinical Trial of SIBP-A16 Injection in Healthy Adults
News(1)
- Sanofi targets late-phase and commercial M&A to offset looming Dupixent declineFocused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported thi…biospace · 19d ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that